MX2022011879A - Derivados de trapidilo marcados isotopicamente. - Google Patents
Derivados de trapidilo marcados isotopicamente.Info
- Publication number
- MX2022011879A MX2022011879A MX2022011879A MX2022011879A MX2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A
- Authority
- MX
- Mexico
- Prior art keywords
- isotopically
- labelled
- trapidil derivatives
- parkinson
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000347P | 2020-03-26 | 2020-03-26 | |
| US202063063846P | 2020-08-10 | 2020-08-10 | |
| PCT/US2021/024226 WO2021195425A1 (en) | 2020-03-26 | 2021-03-25 | Isotopically-labelled trapidil derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011879A true MX2022011879A (es) | 2023-01-11 |
Family
ID=77892379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011879A MX2022011879A (es) | 2020-03-26 | 2021-03-25 | Derivados de trapidilo marcados isotopicamente. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12508267B2 (https=) |
| EP (1) | EP4125853A4 (https=) |
| JP (2) | JP7730336B2 (https=) |
| KR (1) | KR20230013023A (https=) |
| CN (3) | CN116496279B (https=) |
| AU (1) | AU2021244241A1 (https=) |
| CA (1) | CA3177066A1 (https=) |
| IL (1) | IL296788A (https=) |
| MX (1) | MX2022011879A (https=) |
| WO (1) | WO2021195425A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7049683B2 (ja) | 2016-04-04 | 2022-04-07 | シノピア バイオサイエンシーズ，インク． | トラピジルを使用する錐体外路症候群の処置 |
| MX2022011879A (es) * | 2020-03-26 | 2023-01-11 | Sinopia Biosciences Inc | Derivados de trapidilo marcados isotopicamente. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4739044A (en) | 1985-06-13 | 1988-04-19 | Amgen | Method for derivitization of polynucleotides |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IT1222414B (it) | 1987-07-31 | 1990-09-05 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| US5770358A (en) | 1991-09-18 | 1998-06-23 | Affymax Technologies N.V. | Tagged synthetic oligomer libraries |
| JP3195391B2 (ja) | 1991-11-14 | 2001-08-06 | エスエス製薬株式会社 | 徐放性トラピジル錠 |
| HU227530B1 (en) | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| US6033854A (en) | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
| US5348853A (en) | 1991-12-16 | 1994-09-20 | Biotronics Corporation | Method for reducing non-specific priming in DNA amplification |
| US5567583A (en) | 1991-12-16 | 1996-10-22 | Biotronics Corporation | Methods for reducing non-specific priming in DNA detection |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| DE19514048A1 (de) | 1995-04-13 | 1996-10-17 | Rentschler Arzneimittel | Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5869717A (en) | 1997-09-17 | 1999-02-09 | Uop Llc | Process for inhibiting the polymerization of vinyl aromatics |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| JP2001322933A (ja) | 2000-05-15 | 2001-11-20 | Ucb Sa | Ｃｄ４０シグナル遮断剤 |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| WO2005007096A2 (en) | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| US20080242657A1 (en) | 2004-03-26 | 2008-10-02 | Marino Michael J | Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists |
| CN101360421B (zh) | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| KR20100019470A (ko) * | 2007-04-30 | 2010-02-18 | 아보트 러보러터리즈 | 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 １ 효소의 억제제 |
| WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009129537A2 (en) | 2008-04-18 | 2009-10-22 | Gary Zabow | Magnetic microstructures for magnetic resonance imaging |
| KR102759126B1 (ko) | 2010-12-30 | 2025-01-24 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| KR101534395B1 (ko) | 2013-08-01 | 2015-07-09 | 서울대학교산학협력단 | 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물 |
| WO2017059118A1 (en) | 2015-09-29 | 2017-04-06 | Duke University | Compositions and methods for identifying and treating dystonia disorders |
| US11281170B2 (en) | 2015-12-29 | 2022-03-22 | Jones And Malterer Technology Innovations Incorporated | Multi-point synchronizable and scalable lighting control systems |
| JP7049683B2 (ja) * | 2016-04-04 | 2022-04-07 | シノピア バイオサイエンシーズ，インク． | トラピジルを使用する錐体外路症候群の処置 |
| MX2020007994A (es) * | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| CA3163242A1 (en) | 2019-12-02 | 2021-06-10 | Aarash BORDBAR | Treating cognitive disorders using trapidil |
| MX2022011879A (es) | 2020-03-26 | 2023-01-11 | Sinopia Biosciences Inc | Derivados de trapidilo marcados isotopicamente. |
| US20230242538A1 (en) | 2020-06-24 | 2023-08-03 | Yale University | PanK Modulators and Methods Using Same |
-
2021
- 2021-03-25 MX MX2022011879A patent/MX2022011879A/es unknown
- 2021-03-25 IL IL296788A patent/IL296788A/en unknown
- 2021-03-25 AU AU2021244241A patent/AU2021244241A1/en active Pending
- 2021-03-25 CA CA3177066A patent/CA3177066A1/en active Pending
- 2021-03-25 CN CN202310374367.9A patent/CN116496279B/zh active Active
- 2021-03-25 JP JP2022558003A patent/JP7730336B2/ja active Active
- 2021-03-25 CN CN202511776120.5A patent/CN121550230A/zh active Pending
- 2021-03-25 KR KR1020227037235A patent/KR20230013023A/ko active Pending
- 2021-03-25 EP EP21774988.6A patent/EP4125853A4/en active Pending
- 2021-03-25 WO PCT/US2021/024226 patent/WO2021195425A1/en not_active Ceased
- 2021-03-25 CN CN202180038452.7A patent/CN115916180A/zh active Pending
-
2022
- 2022-09-23 US US17/934,680 patent/US12508267B2/en active Active
-
2025
- 2025-08-14 JP JP2025135217A patent/JP2025183224A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202202502A (zh) | 2022-01-16 |
| JP7730336B2 (ja) | 2025-08-27 |
| CN116496279B (zh) | 2025-12-12 |
| CN116496279A (zh) | 2023-07-28 |
| EP4125853A1 (en) | 2023-02-08 |
| AU2021244241A1 (en) | 2022-11-24 |
| KR20230013023A (ko) | 2023-01-26 |
| US20230102580A1 (en) | 2023-03-30 |
| JP2023519289A (ja) | 2023-05-10 |
| JP2025183224A (ja) | 2025-12-16 |
| TW202547838A (zh) | 2025-12-16 |
| WO2021195425A1 (en) | 2021-09-30 |
| IL296788A (en) | 2022-11-01 |
| CN115916180A (zh) | 2023-04-04 |
| CA3177066A1 (en) | 2021-09-30 |
| EP4125853A4 (en) | 2024-07-03 |
| CN121550230A (zh) | 2026-02-24 |
| US12508267B2 (en) | 2025-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| LUC00011I2 (https=) | ||
| WO2008103472A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| DK1800644T3 (da) | Anordning til massage med konstant tryk | |
| MX388912B (es) | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| MX2022011879A (es) | Derivados de trapidilo marcados isotopicamente. | |
| GB0416508D0 (en) | Therapeutic agents | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| TW200509896A (en) | Analeptic and drug combinations | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| PL4284387T3 (pl) | Terapia podnosząca poziom NAD w chorobie Parkinsona | |
| MX2023003032A (es) | Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer. | |
| GB0410238D0 (en) | Therapeutic agents | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| MX2024007043A (es) | Purinas y métodos de uso. | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
| WO2019014322A8 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
| MX2023009024A (es) | Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos. |